美农生物
(301156)
| 流通市值：9.63亿 | | | 总市值：20.33亿 |
| 流通股本：6878.20万 | | | 总股本：1.45亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 340,192,520.78 | 207,705,721.73 | 97,906,175.23 | 504,419,868.4 |
| 营业收入 | 340,192,520.78 | 207,705,721.73 | 97,906,175.23 | 504,419,868.4 |
| 利息收入 | - | - | - | 0 |
| 已赚保费 | - | - | - | 0 |
| 手续费及佣金收入 | - | - | - | 0 |
| 二、营业总成本 | 307,311,369.47 | 188,074,708.83 | 88,010,714.31 | 446,464,198.73 |
| 营业成本 | 242,926,229.13 | 149,364,198.01 | 70,042,172.29 | 353,441,513.65 |
| 利息支出 | 0 | 0 | 0 | 0 |
| 手续费及佣金支出 | 0 | 0 | 0 | 0 |
| 退保金 | 0 | 0 | 0 | 0 |
| 赔付支出净额 | 0 | 0 | 0 | 0 |
| 提取保险合同准备金净额 | 0 | 0 | 0 | 0 |
| 保单红利支出 | 0 | 0 | 0 | 0 |
| 分保费用 | 0 | 0 | 0 | 0 |
| 税金及附加 | 1,975,993.4 | 1,312,018.91 | 555,364.98 | 2,795,631.24 |
| 销售费用 | 26,940,262.53 | 17,400,564.02 | 7,996,293.59 | 37,612,191.79 |
| 管理费用 | 23,251,976.06 | 14,610,727.28 | 6,599,951.21 | 35,446,104.78 |
| 研发费用 | 14,506,680.38 | 8,356,772.3 | 4,123,227.36 | 21,965,539.8 |
| 财务费用 | -2,289,772.03 | -2,969,571.69 | -1,306,295.12 | -4,796,782.53 |
| 其中:利息费用 | -42,511.47 | -49,678.49 | 12,517.23 | -159,455.94 |
| 其中:利息收入 | 2,428,821.06 | 1,852,343.98 | 1,101,651.11 | 3,893,962.47 |
| 加:公允价值变动收益 | 727,222.25 | 368,168.78 | 535,835.98 | -13,743.65 |
| 加:投资收益 | 687,197.1 | 179,583.79 | -364,692.95 | 4,113,681.29 |
| 净敞口套期收益 | 0 | 0 | 0 | 0 |
| 汇兑收益 | 0 | 0 | 0 | 0 |
| 资产处置收益 | 353,254.76 | 20,077.01 | 0 | 34,978.45 |
| 资产减值损失(新) | -982,809.01 | -262,960.37 | -340,846.43 | -882,636.22 |
| 信用减值损失(新) | -668,622.45 | 42,674.45 | 574,980.06 | 2,834,995.9 |
| 其他收益 | 1,739,613.84 | 1,419,597.94 | 642,004.64 | 2,663,396.39 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 34,737,007.8 | 21,398,154.5 | 10,942,742.22 | 66,706,341.83 |
| 加:营业外收入 | 1,500,002.06 | 1,500,000 | 0 | 3,875,968.69 |
| 减:营业外支出 | 56,555.2 | 52,162.04 | 22,153.85 | 362,500.45 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 36,180,454.66 | 22,845,992.46 | 10,920,588.37 | 70,219,810.07 |
| 减:所得税费用 | 4,568,832.45 | 2,854,283.32 | 1,336,665.16 | 7,174,497.28 |
| 六、净利润 | 31,611,622.21 | 19,991,709.14 | 9,583,923.21 | 63,045,312.79 |
| 持续经营净利润 | 31,611,622.21 | 19,991,709.14 | 9,583,923.21 | 63,045,312.79 |
| 终止经营净利润 | 0 | - | - | - |
| 归属于母公司股东的净利润 | 31,611,622.21 | 19,991,709.14 | 9,583,923.21 | 63,045,312.79 |
| 少数股东损益 | 0 | - | - | - |
| (一)基本每股收益 | 0.22 | 0.14 | 0.09 | 0.56 |
| (二)稀释每股收益 | 0.22 | 0.14 | 0.09 | 0.56 |
| 八、其他综合收益 | 0 | - | - | - |
| 归属于母公司股东的其他综合收益 | 0 | - | - | - |
| 九、综合收益总额 | 31,611,622.21 | 19,991,709.14 | 9,583,923.21 | 63,045,312.79 |
| 归属于母公司股东的综合收益总额 | 31,611,622.21 | 19,991,709.14 | 9,583,923.21 | 63,045,312.79 |
| 归属于少数股东的综合收益总额 | 0 | - | - | - |
| 公告日期 | 2024-10-30 | 2024-08-28 | 2024-04-25 | 2024-04-09 |
| 审计意见(境内) | | | | 标准无保留意见 |